Spero Therapeutics (SPRO) Releases Earnings Results, Beats Expectations By $0.04 EPS

Spero Therapeutics (NASDAQ:SPRO) released its earnings results on Thursday. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.04, Zacks reports. The business had revenue of $0.66 million during the quarter, compared to analysts’ expectations of $0.66 million. Spero Therapeutics had a negative net margin of 1,479.91% and a negative return on equity of 132.11%.

SPRO opened at $8.57 on Friday. The stock has a market cap of $156.79 million and a P/E ratio of -0.48. Spero Therapeutics has a twelve month low of $7.80 and a twelve month high of $19.00.

A number of analysts have recently commented on the stock. Zacks Investment Research raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 target price for the company in a research note on Friday, October 19th. Bank of America cut shares of Spero Therapeutics from a “neutral” rating to an “underperform” rating and cut their target price for the stock from $19.00 to $9.00 in a research note on Tuesday, October 16th. Oppenheimer set a $30.00 target price on shares of Spero Therapeutics and gave the stock a “buy” rating in a research note on Sunday, September 30th. Finally, Cantor Fitzgerald set a $27.00 target price on shares of Spero Therapeutics and gave the stock a “buy” rating in a research note on Thursday, September 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Spero Therapeutics has an average rating of “Buy” and a consensus target price of $21.58.

A hedge fund recently raised its stake in Spero Therapeutics stock. Bank of New York Mellon Corp increased its holdings in shares of Spero Therapeutics Inc (NASDAQ:SPRO) by 73.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,689 shares of the company’s stock after acquiring an additional 10,490 shares during the quarter. Bank of New York Mellon Corp owned about 0.14% of Spero Therapeutics worth $363,000 at the end of the most recent reporting period. 38.55% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Spero Therapeutics (SPRO) Releases Earnings Results, Beats Expectations By $0.04 EPS” was first reported by WKRB News and is the property of of WKRB News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.wkrb13.com/2018/11/10/spero-therapeutics-spro-releases-earnings-results-beats-expectations-by-0-04-eps.html.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

Recommended Story: Relative Strength Index

Earnings History for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply